Bioanalysis and Analytical Services Research Group
The principal areas of interest for the research projects of the group are the following:
- Oxygen administration: Areas of study: erythropoietin, genetic therapy, blood transfusions.
- Growth: Areas of study: growth hormone, growth hormone secretagogues, chorionic gonadotropin, steroids, genetic therapy, and glycoconjugates.
- Biomarkers for exposure to drugs of abuse: Areas of study: nicotine and alcohol.
Human Pharmacology and Neurosciences Clinical Research Group
Studies are carried out on individuals to determine the effects caused by the administration of one or more drugs simultaneously, reproducing the consumer’s usual social habits.
We are examining the human beneficial health effects of certain diet components such as polyphenols from olive oil, soya, and green tea in the prevention of cardiovascular pathologies and, additionally, in the treatment of addictions, neurodegenerative pathology and causes of intellectual disability.
Current lines of research include:
- Clinical pharmacology of drugs of abuse:
The evaluation of the pharmacological and toxicological effects induced by drugs of abuse in recreational consumers with substance abuse disorders (poly-consumers) with single or repeated doses (pharmacodynamics, pharmacokinetics, pharmacogenetics) or at medium/long term (alterations in cognitive performance, prevalence of psychopathology). The evaluation of new therapeutic approaches to drugs of abuse addiction.
- Eating disorders and cognition
The interaction of environmental factors, including diet, with the health of individuals, particularly with respect to their neurocognitive function including their interactions with specifically biological factors (endocrine and genetic) or sensorial ones, and situations with the risk of suffering cardiovascular pathologies, or extreme weight categories (eating disorders, obesity).
- Genetic diseases which are responsible for intellectual disability and neurodegenerative conditions.
The study of genetic diseases (e.g. Down Syndrome, Fragile X Syndrome) and neurodegenerative conditions (e.g. Alzheimer’s Disease) which lead to intellectual disability or cognitive deterioration. The activity of nutraceuticals on neuronal plasticity in the therapy of these pathologies is being evaluated in order to improve cognitive performance.
The Proteomic Group has developed both internal projects (UPF, IMIM, BBRP) and external ones focused on areas that include:
- research into the tissue-plasminogen activator receptors in the pancreatic cells with the aim of elucidating the mitogenic signalling mechanisms of this protein.
- characterization of the post-translational modifications arising from oxidative stress in amyloidosis and other conditions.
- identification of selected phenotypes for the overexpression of Bcl-xL in breast cancer cells.
- identification of the proteins characteristic of the resistance patterns of Acinetobacter baumannii, multiresistant strains associated with nosocomial infections.